TY - JOUR AU - Tsuburaya, Akira AU - Morita, Satoshi AU - Kodera, Yasuhiro AU - Kobayashi, Michiya AU - Shitara, Kohei AU - Yamaguchi, Kensei AU - Yoshikawa, Takaki AU - Yoshida, Kazuhiro AU - Yoshino, Shigefumi AU - Sakamoto, Jun-ichi PY - 2012 DA - 2012/07/23 TI - A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II) JO - BMC Cancer SP - 307 VL - 12 IS - 1 AB - On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with S-1 plus cisplatin (SP), which is considered standard therapy in Japan, has not yet been assessed. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-12-307 DO - 10.1186/1471-2407-12-307 ID - Tsuburaya2012 ER -